Log in/ Sign up

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with US prices falling for GLP-1 treatments from Novo Nordisk and Eli Lilly

02/02 23:40
Bullish
Bearish

Trending News